Globe Newswire (Tue, 3-Feb 7:30 AM ET)
Globe Newswire (Tue, 13-Jan 7:30 AM ET)
PRNewswire (Thu, 8-Jan 8:13 PM ET)
PRNewswire (Thu, 8-Jan 10:00 AM ET)
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
Globe Newswire (Thu, 8-Jan 7:30 AM ET)
Globe Newswire (Tue, 6-Jan 12:41 PM ET)
Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program
Globe Newswire (Tue, 6-Jan 7:30 AM ET)
Globe Newswire (Wed, 24-Dec 10:30 AM ET)
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
Globe Newswire (Thu, 18-Dec 7:30 AM ET)
Market Chameleon (Fri, 14-Nov 2:33 AM ET)
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Anavex Life Sciences Corp. trades on the NASDAQ stock market under the symbol AVXL.
As of February 5, 2026, AVXL stock price declined to $3.81 with 1,383,288 million shares trading.
AVXL has a beta of 1.20, meaning it tends to be more sensitive to market movements. AVXL has a correlation of 0.05 to the broad based SPY ETF.
AVXL has a market cap of $340.42 million. This is considered a Small Cap stock.
In the last 3 years, AVXL traded as high as $14.44 and as low as $2.86.
The top ETF exchange traded funds that AVXL belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.
AVXL has underperformed the market in the last year with a price return of -57.0% while the SPY ETF gained +13.8%. AVXL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -49.0% and -28.1%, respectively, while the SPY returned +0.6% and -1.1%, respectively.
AVXL support price is $3.96 and resistance is $4.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVXL shares will trade within this expected range on the day.
